<DOC>
	<DOCNO>NCT00293670</DOCNO>
	<brief_summary>To compare intermittent androgen deprivation ( LHRHa treatment ) continuous androgen deprivation ( LHRHa treatment orchidectomy )</brief_summary>
	<brief_title>FINNPROSTATE Study VII : Intermittent Versus Continuous Androgen Deprivation Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>• Inclusion Criteria ( runin period ) : T1T4 , metastatic ( M1 ) prostate cancer T1T4 , nonmetastatic ( M0 ) prostate cancer PSA &gt; 60 ng/mL T3T4 , nonmetastatic ( M0 ) prostate cancer PSA &gt; 20ng/mL T1T4 , N+ prostate cancer WHO performance status 02 Written inform consent • Inclusion criterion randomise period : Patients fulfil entry criterion runin period Patients complete 24week runin period Patients respond 24week runin period decrease PSA &lt; 10 ng/mL . If baseline &lt; 20ng/mL , least 50 % decrease baseline measurement require Exclusion Criteria ( runin period ) : Any previous concurrent treatment prostate cancer , except TURP , 5alpha reductase inhibitor , radical prostatectomy radiotherapy Any medication/treatment affect sex hormone status</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
</DOC>